A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin

Journal of Veterinary Emergency and Critical Care

Volumn 21, Issue 5, 2011, Pages 471-483

  Spurlock, Nicole K ^a   Prittie, Jennifer E ^a  

^a ANIMAL MEDICAL CENTER   (United States)

Author keywords

hIVIG; Immune mediated disease; Transfusion medicine

Indexed keywords

ANIMALIA;

IMMUNOGLOBULIN;

ANIMAL; ANIMAL DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD GROUP INCOMPATIBILITY; CAT; CAT DISEASE; DOG; DOG DISEASE; ERYTHEMA MULTIFORME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; REVIEW;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; BLOOD GROUP INCOMPATIBILITY; CAT DISEASES; CATS; DOG DISEASES; DOGS; ERYTHEMA MULTIFORME; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS;

EID: 84862605617     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2011.00676.x     Document Type: Review

References (62)

1. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
2. Scott-Moncreiff JC, Reagan JW, Glickman LT, et al. Treatment of nonregenerative anemia with human gamma-globulin in dogs. J Am Vet Med Assoc 1995; 206:1895-1900.
3. Scott-Moncrieff JC, Reagan JW, Synder PW, et al. Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 1997; 210(11):1623-1627.
4. Emmi L, Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002; 23:S1-S8.
5. Lemiwux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005; 42:839-848.
6. Scott-Moncrieff JCR, Regan WJ. Human intravenous immunoglobulin therapy. Semin Vet Med Surg (Small Anim) 1997; 12:178-185.
7. Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transplant 2005; 11(12):1469-1480.
8. Vaccaro J, Zhou J, Ober RJ. Engineering the Fc region of immunoglobulin G to modulate en vivo antibody levels. Nat Biotechnol 2005; 23:1283-1288.
9. Trotman TK, Philips H, Fordyce H, et al. Treatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs. J Am Anim Hosp Assoc 2006; 42:312-320.
10. Knezevic-Maramica, Margot S. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43(10):1460-1480.
11. Reagan WJ, Scott-Moncrieff C, Christian J, et al. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Am J Vet Res 1998; 59(12):1536-1574.
12. Hinn AC, Olivry T, Luther PB, et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in the dog: clinical classification, drug exposure, and histopathological correlations. Vet Allerg Clin Immunol 1998; 6:13-20.
13. Prins C, Kerdel FA, Padilla RS. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139:26-32.
14. Stella M, Cassano P, Bollero D. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203:45-49.
15. Foster R, Suri A, Filate W, et al. Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfus Med 2010; 20(6):403-408.
16. Alejandria MM, Lansang MAD, Dans LF, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2002; Issue 1. Art. No.: CD001090. doi: 10.1002/14651858.CD001090.
17. De Albuquerque CR, Sato MN, Da Silva Huarte AJ. IgG anti IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000; 20:70-82.
18. Chen C, LH Danekas, TA Ratko, et al. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacolther 2000; 34:295-915.
19. Kellerman DL, Bruyette DS. Intravenous human immunoglobulin for treatment of immune-mediated hemolytic anemia in 13 dogs. J Vet Intern Med 1997; 11(6):327-332.
20. Grundy SA, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc 2001; 218(4):543-546.
21. Gerber B, Steger A, Hassig M, et al. Use of human intravenous immunoglobulin in dogs with primary immune mediated anemia. Schweiz Arch Tierheilkd 2002; 144(4):180-185.
22. Whelan M, O'Toole T, Chan DL, et al. Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia. J Vet Emerg Crit Care 2009; 19(2):158-164.
23. Bianco D, Armstrong J, Washabau R. Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. J Vet Intern Med 2007; 21:694-699.
24. Rozanski EA, Callan MB, Hughes D, et al. Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment of severe immune-mediated thrombocytopenia in dogs. J Am Vet Med Assoc 2002; 220:477-481.
25. Bianco D, Armstrong J, Washabau R. A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs. J Vet Intern Med 2009; 23:1071-1078.
26. Bianco D, Hardy M. Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog. J Am Anim Hosp Assoc 2009; 45:147-150.
27. Nuttall TJ, Malham T. Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. J Small Anim Pract 2004; 45:35-36.
28. Byrne KP, Giger U. Use of human immunoglobulin for treatment of severe erythema multiforme in a cat. J Am Vet Med Assoc 2002; 220:197-201.
29. Rahilly L, Keating J, O'Toole T. The use of intravenous human immunoglobulin in treatment of severe pemphigus foliaceus in a dog. J Vet Intern Med 2006; 20:1483-1486.
30. Marsella R. Canine pemphigus complex: pathogenesis and clinical presentation. Compend Contin Educ Pract Vet 2000; 22:568-572.
31. Grozdanic S, Harper M, Kecova H. Antibody-mediated retinopathies in canine patients: mechanism, diagnosis, and treatment modalities. Vet Clin N Am Small Anim Pract 2008; 38(2):361-387.
32. Abelson A, Shelton D, Whelan M, et al. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs. J Vet Emerg Crit Care 2009; 19(4):369-374.
33. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it. Transfusion 2006; 46(5):741-753.
34. Affolter VK, von Tscharner C. Cutaneous drug reactions: a retrospective study of histopathological changes and their correlation with the clinical disease. Vet Dermatol 1993; 4:79-86.
35. Jolles S, Hughes J, Whittaker S. Dermatological uses of high dose intravenous immunoglobulin. Arch Dermatol 1998; 134:80-86.
36. Trent JT, Kersner RS Tomanelli P. Analysis of intravenous immunoglobulin for treatment of toxic epidermal necrolysis using SCORTEN: The Universiy of Miami experience. Arch Dermatol 2003; 139:39-43.
37. Ahmed AR, Dahl M. Consensus statement of the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139:1051-1059.
38. Dahl MV, Bridges AG. Intravenous immune globulin: fighting antibodies with antibodies. J Am Acad Dermatol 2004; 45:775-783.
39. Bellhorn RW, Murphy CJ, Thirkill CE. Anti-retinal immunoglobulins in canine ocular diseases. Semin Vet Med Surg (Small Anim) 1988; 3:28-32.
40. Keller RL, Kania SA, Hendrix DV. Evaluation of canine serum for the presence of antiretinal autoantibodies in sudden acquired retinal degeneration syndrome. Vet Opththalmol 2006; 9:195-200.
41. Miller PE, Galbreath EJ, Kehren JC. Photoreceptor cell death by apoptosis in dogs with sudden acquired retinal degeneration syndrome. Am J Vet Res 1998; 59:149-152.
42. Keltner JL, Thrikill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and review of 51 published cases. J Neuroopthalmol 2001; 21:173-187.
43. Guy J, Aptsisauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 1999; 117:471-477.
44. Ettinger SJ, Feldman EC. Textbook of Veterinary Internal Medicine, 5th ed. Philadelphia, PA: WB Saunders Co; 2000, pp. 675-677.
45. Zinman L, Nq E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68(11):837-884.
46. Marie I, Maurey G, Herve F, et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006; 155:714-721.
47. Nydegge UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21(3):171-185.
48. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43(10):1460-1480.
49. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97(suppl 1):79-83.
50. Sekul E, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose Intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121:259-262.
51. Baba R, Shibata A, Tsurusawa M. Single high-dose intravenous immunoglobulin therapy for Kawasaki disease increases plasma viscosity. Circ J 2005; 69:962-4.
52. Tsuchiya R, Akutsu Y, Scott MA, et al. Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs. J Vet Intern Med 2009; 23:1164-1169.
53. Cayco A, Perazella M, Hayslett J. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8(11):1788-1794.
54. Orbach H, Katz I, Sherer Y, et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29:173-184.
55. Kroez M, Kanzy EJ, Gronsk P. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 2003; 31(4):277-286.
56. Murphy E, Martin S, Valino-Patterson J. Developing practice guidelines for the administration of intravenous immunoglobulin. J Infus Nurs 2005; 28(4):265-272.
57. Kirmse J. The nurse's role in administration of intravenous immunoglobulin therapy. Home Healthc Nurse 2009; 27(2):104-111.
58. Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005; 28(6):366-374.
59. Benesch M, Kerbl R, Lackner H, et al. Low-dose vs. high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized, single-center trial. J Pediatr Hematol Oncol 2003; 25:797-800.
60. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004; 114:936-942.
61. Gardulf A, Hammarstrom L, Smith E. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338(760):162-166.
62. Costa-Caravalo BT, Lin M, Sole D, et al. Metabolic and hematologic changes occurring after rapid intravenous infusion of gammaglobulin in patients with antibody deficiency syndromes. Sao Paulo Med 1998; 116(5):1815-1820.